Your browser doesn't support javascript.
SARS-CoV-2 Infection Rate in Patients With Cancer and Health Care Workers in a Chemoradiotherapy Unit During the Pandemic: A Prospective Cohort in Mexico.
Meneses-Medina, Monica Isabel; Hernandez-Felix, Jorge Humberto; Anaya-Sánchez, Luis Guillermo; Valenzuela-Vidales, Ana Karen; Rosas-Camargo, Vanessa; Martos-Armendariz, Edgar Omar; Torres-Valdiviezo, Lucero Itzel; Cedro-Tanda, Alberto; Noguez-Ramos, Alejandro; Herrera-Montalvo, Luis Alonso; Hidalgo-Miranda, Alfredo; Valdez-Echeverria, Raymundo David; Galindo-Fraga, Arturo; Huitzil-Meléndez, Fidel David.
  • Meneses-Medina MI; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Hernandez-Felix JH; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Anaya-Sánchez LG; Facultad de Medicina, Universidad Autónoma de Coahuila Unidad Torreón, Torreón, México.
  • Valenzuela-Vidales AK; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Rosas-Camargo V; Escuela de Ciencias, Departamento de Ciencias de la Salud, Universidad de las Américas Puebla, Puebla, México.
  • Martos-Armendariz EO; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Torres-Valdiviezo LI; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Cedro-Tanda A; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Noguez-Ramos A; Facultad de Ciencias de la Salud, Universidad Juárez del Estado de Durango, Gómez Palacio, México.
  • Herrera-Montalvo LA; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Hidalgo-Miranda A; Escuela de Ciencias, Departamento de Ciencias de la Salud, Universidad de las Américas Puebla, Puebla, México.
  • Valdez-Echeverria RD; Instituto Nacional de Medicina Genómica, Ciudad de México, México.
  • Galindo-Fraga A; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
  • Huitzil-Meléndez FD; Instituto Nacional de Medicina Genómica, Ciudad de México, México.
JCO Glob Oncol ; 7: 1639-1646, 2021 09.
Article in English | MEDLINE | ID: covidwho-1571950
ABSTRACT

PURPOSE:

Cancer treatment during the COVID-19 pandemic represents a challenge. Hospital visits to receive treatment and interaction with health care workers (HCW) represent potential contagious events. We aimed to determine SARS-CoV-2 infection rate among patients with cancer and HCW of a chemoradiotherapy unit localized in a center designated as a COVID-19 priority facility in Mexico City. We also determined the diagnostic performance of a clinical questionnaire (CQ) as a screening tool and anti-SARS-CoV-2 antibody seroconversion rate.

METHODS:

HCW and patients with solid tumors attending the chemoradiotherapy unit signed informed consent. To determine SARS-CoV-2 infection rate prospectively, a nasopharyngeal swab for SARS-CoV-2 real-time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) was performed every 2 weeks in asymptomatics. An electronic CQ interrogating COVID-19-related symptoms was sent daily. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were measured at baseline and at the end of the study period.

RESULTS:

From June to September 2020, we included 130 asymptomatic participants, 44.6% HCW and 55.4% patients with cancer. During a median follow-up of 85 days, 634 nasopharyngeal swabs were performed. Average SARS-CoV-2 monthly incidence was 4.6% (3.15%-7.47%), and cumulative infection rate was 13.8% (18 of 130). Cases were mostly asymptomatic (66%), and no hospitalizations or deaths were recorded. The CQ as a screening tool provided a sensitivity of 27.7%, a positive predictive value of 26.3%, and a positive likelihood ratio of 12. SARS-CoV-2 IgG seroconversion rate was 27.7% among those with a positive RT-PCR.

CONCLUSION:

Patients with cancer on treatment can have uncomplicated COVID-19 outcomes. Biweekly RT-qPCR testing detects asymptomatic infections, prevents transmission, and should be implemented in units to increase patient safety. CQ increase RT-qPCR diagnostic yield and may prioritize testing in resource-deprived settings. Post-infection IgG seroconversion is unreliable.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Mexico Language: English Journal: JCO Glob Oncol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Mexico Language: English Journal: JCO Glob Oncol Year: 2021 Document Type: Article